门脉性肺动脉高压研究进展

doi:10.3969/j.issn.1004-583X.2024.04.010

摘要/Abstract

摘要：

门脉性肺动脉高压指在门静脉高压基础上形成的肺动脉高压,最常见于肝硬化患者。由于其发病率较低,临床表现无明显特异性,诊断有赖于有创检查,临床上常常被漏诊、误诊。且该病药物治疗效果差,虽然肝移植可有效降低肺动脉压力,但严重的肺动脉高压可增加肝移植死亡率,影响预后,因此,临床中需重视该病。本文总结了该病的流行病学、病理生理、发病机制、危险因素、临床表现、诊断和治疗等方面的研究进展,以提高临床上对该病的认识。

关键词: 高血压, 门静脉, 肺动脉高压, 肝硬化, 肝移植

中图分类号:

R657.34

匡竞, 滕双芩, 申彤彤, 闫怡然, 申川, 王玮, 王亚东, 赵彩彦. 门脉性肺动脉高压研究进展[J]. 临床荟萃, 2024, 39(4): 352-356.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.04.010

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I4/352

图/表 1

参考文献 40

[1]	Tamura Y, Tamura Y, Taniguchi Y, et al. Current clinical understanding and effectiveness of portopulmonary hypertension treatment[J]. Front Med (Lausanne), 2023, 10:1142836.
[2]	Jasso-Baltazar EA, Peña-Arellano GA, Aguirre-Valadez J, et al. Portopulmonary hypertension: An updated review[J]. Transplant Direct, 2023, 9(8):e1517. doi: 10.1097/TXD.0000000000001517 pmid: 37492078
[3]	Sithamparanathan S, Nair A, Thirugnanasothy L, et al. Survival in portopulmonary hypertension: Outcomes of the united kingdom national pulmonary arterial hypertension registry[J]. J Heart Lung Transplant, 2017, 36(7):770-779.
[4]	Navarro-Vergara DI, Roldan-Valadez E, Cueto-Robledo G, et al. Portopulmonary hypertension: Prevalence, clinical and hemodynamic features[J]. Curr Probl Cardiol, 2021, 46(3):100747.
[5]	Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites[J]. Gut, 2003, 52(9):1355-1362. doi: 10.1136/gut.52.9.1355 pmid: 12912870
[6]	Weinfurtner K, Forde K. Hepatopulmonary syndrome and portopulmonary hypertension: Current status and implications for liver transplantation[J]. Curr Hepatol Rep, 2020, 19(3):174-185. doi: 10.1007/s11901-020-00532-y pmid: 32905452
[7]	Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38(4):570-580. doi: 10.1111/liv.13589 pmid: 28921803
[8]	Thomas C, Glinskii V, de Jesus Perez V, et al. Portopulmonary hypertension: From bench to bedside[J]. Front Med (Lausanne), 2020, 7:569413.
[9]	Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: Clinical studies update[J]. Gut Liver, 2021, 15(5):666-676. doi: 10.5009/gnl20032 pmid: 33071239
[10]	Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease[J]. Am J Respir Crit Care Med, 2009, 179(9):835-842.
[11]	Al-Naamani N, Krowka MJ, Forde KA, et al. Estrogen signaling and portopulmonary hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)[J]. Hepatology, 2021, 73(2):726-737.
[12]	Castaño G, Sookoian S. Female sex and autoimmune hepatitis and the risk of portopulmonary hypertension[J]. Hepatology, 2008, 48(6):2090. doi: 10.1002/hep.22599 pmid: 19026001
[13]	Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension[J]. Hepatology, 2008, 48(1):196-203. doi: 10.1002/hep.22275 pmid: 18537192
[14]	DuBrock HM, Cartin-Ceba R, Channick RN, et al. Sex differences in portopulmonary hypertension[J]. Chest, 2021, 159(1):328-336. doi: 10.1016/j.chest.2020.07.081 pmid: 32798521
[15]	Shao Y, Yin X, Qin T, et al. Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: A case-control study[J]. Biomed Res Int, 2021, 2021:5595614.
[16]	Miyasaka A, Yoshida Y, Suzuki A, et al. A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection[J]. Clin J Gastroenterol, 2020, 13(1):90-96. doi: 10.1007/s12328-019-01016-3 pmid: 31292842
[17]	Kawanaka H, Akahoshi T, Kinjo N, et al. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension[J]. Br J Surg, 2014, 101(12):1585-1593. doi: 10.1002/bjs.9622 pmid: 25200126
[18]	Segraves JM, Cartin-Ceba R, Leise MD, et al. Relationship between portopulmonary hypertension and splenectomy: Mayo clinic experience and review of published works[J]. Hepatol Res, 2018, 48(3):e340-e346.
[19]	Huang L, Li W, Yang T, et al. Association between splenectomy and portal hypertension in the development of pulmonary hypertension[J]. Pulm Circ, 2020, 10(1):2045894019895426.
[20]	Korbitz PM, Gallagher JP, Samant H, et al. Performance of echocardiography for detection of portopulmonary hypertension among liver transplant candidates: Meta-analysis[J]. Clin Transplant, 2020, 34(11):e13995.
[21]	Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: An analysis of cutoff values[J]. Liver Transpl, 2013, 19(6):602-610.
[22]	Yin X, Shao Y, Zhang Y, et al. Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: A meta-analysis[J]. PeerJ, 2020, 8:e9243.
[23]	Nikolic I, Yung LM, Yang P, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension[J]. Am J Respir Crit Care Med, 2019, 199(7):891-902.
[24]	Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension[J]. Cell Mol Life Sci, 2017, 74(16):2979-2995. doi: 10.1007/s00018-017-2510-4 pmid: 28447104
[25]	DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, et al. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension[J]. Pulmonary circulation, 2016, 6(4):498-507. doi: 10.1086/688489 pmid: 28090291
[26]	Hayashi R, Kogiso T, Kikuchi N, et al. Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates[J]. PLoS ONE, 2022, 17(4):e0267125.
[27]	Yoshimaru K, Matsuura T, Takahashi Y, et al. The efficacy of serum brain natriuretic peptide for the early detection of portopulmonary hypertension in biliary atresia patients before liver transplantation[J]. Pediatr Transplant, 2018, 22(5):e13203.
[28]	Zhang R, Li T, Shao Y, et al. Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13:991568.
[29]	Tokushige K, Kogiso T, Egawa H. Current therapy and liver transplantation for portopulmonary hypertension in Japan[J]. J Clin Med, 2023, 12(2):562.
[30]	Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): A multicentre, randomised, double-blind, placebo-controlled, phase 4 trial[J]. Lancet Respir Med, 2019, 7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8 pmid: 31178422
[31]	Krowka M, Cottreel E, Hoeper MM, et al. Macitentan improves risk categorization for liver transplant mortality in patients with portopulmonary hypertension: A PORTICO study post hoc analysis[J]. Liver Transpl, 2020, 26(7):935-940.
[32]	Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial[J]. J Heart Lung Transplant, 2020, 39(5):464-472.
[33]	Rossi R, Talarico M, Schepis F, et al. Effects of sildenafil on right ventricle remodelling in portopulmonary hypertension[J]. Pulm Pharmacol Ther, 2021, 70:102071.
[34]	Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management[J]. J Hepatol, 2020, 73(1):130-139. doi: S0168-8278(20)30119-7 pmid: 32145258
[35]	Cartin-Ceba R, Halank M, Ghofrani HA, et al. Riociguat treatment for portopulmonary hypertension: A subgroup analysis from the PATENT-1/-2 studies[J]. Pulm Circ, 2018, 8(2):2045894018769305.
[36]	Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial[J]. Lancet Respir Med, 2021, 9(6):573-584.
[37]	Melgosa MT, Ricci GL, García-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension[J]. Liver Transpl, 2010, 16(3):348-356.
[38]	Onoe T, Tanaka A, Ishiyama K, et al. Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: A case report[J]. Surg Case Rep, 2018, 4(1):15. doi: 10.1186/s40792-018-0423-6 pmid: 29417353
[39]	Krowka MJ, Fallon MB, Kawut SM, et al. International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7):1440-1452. doi: 10.1097/TP.0000000000001229 pmid: 27326810
[40]	中华医学会器官移植学分会围手术期管理学组, 中国医师协会外科医师分会器官移植围手术期管理专业委员会. 门静脉性肺动脉高压肝移植围手术期管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2022, 21(1):10-14.

门脉性肺动脉高压研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王沁濡, 尹琴, 李娟, 甘洪玉. 中医药治疗慢性阻塞性肺疾病合并肺动脉高压的研究进展[J]. 临床荟萃, 2024, 39(2): 188-192.
[2]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[3]	梅胜梅, 周俊英. 维生素D缺乏与自身免疫性肝炎相关性研究进展[J]. 临床荟萃, 2021, 36(9): 856-860.
[4]	王园园, 程宁, 林海燕. 慢性乙型肝炎患者血清sST2与肝功能、血小板水平及Ishak评分的相关性[J]. 临床荟萃, 2021, 36(11): 976-980.
[5]	安勤燕, 姜蓉, 康彬, 杜明, 周仁明, 赵洪娟, 段炜, 卢飞, 刘锦铭. 特发性肺动脉高压患者RDW、NT-ProBNP、BigET-1、HMGB1水平变化及临床意义[J]. 临床荟萃, 2021, 36(11): 1001-1004.
[6]	佟印妮, 黄艳册, 郑吉敏. 肝硬化顽固性腹水的治疗[J]. 临床荟萃, 2021, 36(1): 70-74.
[7]	刘双，赵东强. 失代偿期肝硬化治疗中存在的几个问题[J]. 临床荟萃, 2020, 35(7): 647-652.
[8]	程明荣，戴德坚. 贞芪扶正胶囊联合熊去氧胆酸治疗原发性胆汁性胆管炎对甲状腺功能的影响[J]. 临床荟萃, 2020, 35(3): 260-263.
[9]	江萍1，王存凯2，王玉珍2. 血清学指标评估乙型肝炎肝纤维化程度及预后的研究进展[J]. 临床荟萃, 2020, 35(10): 947-951.
[10]	王彦坤1，马俊骥2，张明2. 细胞角蛋白7在肝硬化病理诊断中的作用[J]. 临床荟萃, 2019, 34(2): 124-127.
[11]	黄光明，谷达会，郝亚琴，程文会，何治军. 营养状况对老年肝硬化住院患者临床结局的影响[J]. 临床荟萃, 2019, 34(2): 128-131.
[12]	季强，牛巍巍，霍晓霞，张晓岚. 肝硬化并发食管胃静脉曲张的治疗进展[J]. 临床荟萃, 2019, 34(12): 1123-1126.
[13]	杜少严a，尹硕a，郝文洋b，王意浓b，孙晓彩c，李淑琴c. 硫化氢在肝脏疾病中的研究进展[J]. 临床荟萃, 2019, 34(12): 1127-1130.
[14]	金燕，葛志华，孙源源，徐殊嫣，邵建国. AIMS65评分对肝硬化食管胃静脉曲张出血风险评估的临床研究[J]. 临床荟萃, 2018, 33(6): 498-501.
[15]	段佳悦a，史清峰a，王明光a，戚诚b，闫长青a. 血管内皮生长因子、碱性成纤维细胞生长因子和内皮抑素在肝硬化中的表达及意义[J]. 临床荟萃, 2018, 33(5): 427-430.